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treatment [5]. However, the absolute change in digoxin pharmacokinet-
ics was small and considered not clinically signiﬁcant [5]. In a crossover
study with eight healthy male subjects aged between 23 and 27 years,
25 mg carvedilol increased the mean maximum plasma concentration
and the area under the plasma concentration time curve of digoxin
just when administered orally (single dose of 0.5 mg) [6].
Grunden et al. performed a prospective, double-blind, placebo-
controlled trialwith twenty-twoNewYork Heart Association functional
class II–III patients with idiopathic dilated cardiomyopathy selected
from a clinical trial evaluating the efﬁcacy and hemodynamic effects of
chronic carvedilol treatment in heart failure [7]. Clinical signiﬁcant
changes in serumdigoxin concentrationswere not observed inmost pa-Digoxin is an inotropic agent currently prescribed at a daily dose of
0.125 or 0.25 mg orally [1]. Due to its narrow therapeutic range (0.8 to
2.0 ng/mL), intoxication may occur due to drug interactions or health
status that change digoxin pharmacokinetic parameters [2]. The phar-
macotherapy with this digitalis often requires constant monitoring of
its plasma concentration (Cp) being intoxication avoided by the adjust-
ment of digoxin therapeutic regimen [2]. So it can be considered safe
and well tolerated when dosed appropriately [3].
It is important to highlight that digoxin is inexpensive and then can
be afforded by most patients with heart failure throughout the world
[3]. According to Gheorghiade et al. digoxin reduces hospitalizations in
patients with chronic heart failure and, when combined with β-
blockers, it remains a useful agent to achieve rate control in atrial ﬁbril-
lation [3].
Several major trials have established the cardiovascular beneﬁts
of carvedilol over traditional non-vasodilating β-blockers in patients
with heart failure [4] and this drug is currently used, as well as
digoxin, in the pharmacotherapy of heart failure with systolic dysfunc-
tion [1].
According toWermeling et al. carvedilol increased digoxin's oral bio-
availability (0.25 mg dosage) as well as renal elimination in twelve pa-l Pharmacology, Department of
versity, Rua Professor Hernani
e Janeiro CEP 24.210-130, Brazil.
etas@gmail.com
.tients with mild to moderate hypertension after 2 weeks of concurrent
tients who receive carvedilol concomitantly. Additionally, no patients
required digoxin dosage adjustments and there were no clinically sig-
niﬁcant adverse events directly attributable to an increase of serum di-
goxin concentration [7].
Digoxin is also often coadministeredwith carvedilol in childrenwith
severe ventricular failure [8]. Ratnapalan et al. showed that in eight chil-
dren (age 2 weeks to 8 years), the oral clearance of digoxin was
decreased by half with carvedilol (dose range between 0.08 and
1.06 mg/kg/day); this β-blocker increased serum concentrations of di-
goxin in children and two of them had digoxin toxicity [8].
A crossover study including twenty-four patients (12 males and 12
females, mean patient age 67.8± 8.2 years) with New York Heart Asso-
ciation class II–III heart failure was conducted by Baris et al. to evaluate
the inﬂuence of multiple dose administration of carvedilol (6.25 mg,
two times daily) on thepharmacokinetics of 0.0625–0.25mgoral digox-
in after 7 days of concurrent treatment [9]. In themale group, carvedilol
led to statistically signiﬁcant increase in the area under the plasma con-
centration time curve andmeanmaximumplasma concentration for di-
goxin, with no change in time to peak. However, in the female group,
carvedilol administration did not cause statistically signiﬁcant change
in the area under the plasma concentration time curve, meanmaximum
plasma concentration or time to peak for digoxin. Additionally, in
the male group, carvedilol resulted in a signiﬁcant increase in the area
under the plasma concentration time curve and mean maximum
plasma concentration for digoxin compared with the female group.
These data suggest that men seem to have a higher activity relative
to women for the drug efﬂux transporter P-glycoprotein and that
carvedilol can cause drug interaction with digoxin following the inhibi-
tion of P-glycoprotein-mediated transcellular transport of digoxin in
males [9].
Fig. 1. Digoxin plasma concentration (Cp, ng·mL−1) measured during 24 h after this
drug administration alone (Control–Carvedilol na ve) or in combination with carvedilol
(carvedilol) in patients with heart failure. *P b 0.05.
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andmultiple dose administration of carvedilol on the pharmacokinetics
of oral digoxin in male younger patients with heart failure.
This prospective study was conducted at Instituto Nacional de
Cardiologia (INC) at Rio de Janeiro (Brazil) and was approved by the
local Ethics Committee on Human Research (0306/07-12-10). Patients
admitted to the cardiomyopathy ward of INC were recruited through a
pharmacotherapeutic screening. Eligibility criteria involved (1) male
patients using digoxin 0.125–0.250 mg p.o. (8:00 am) during at least
5 days, (2) aged between 21 and 60 years-old, and (3) New York
Heart Association class III. Eligible patients provided a consent form
after receiving verbal and written details regarding the procedures
adopted in the study. Enrollment was stratiﬁed into two groups on the
basis of the current adherence of patients to digoxin therapy alone
(Control — Carvedilol naive) or in combination with carvedilol
25 mg p.o. twice a day (10:00 am/10:00 pm) administration during at
least 3 days (carvedilol). Blood samples were collected at 6 different
points along 24 h after digoxin oral administration. Measurements of
digitalis plasma concentration (Cp) were performed using immuno-
chemiluminescence method [10]. Pharmacokinetic parameters were
determined for each group: area under the curve (AUC), calculated by
the linear trapezoidal rule; maximum plasma concentration (Cmax);
time to Cmax observation (Tmax) and the ratio CL/F (clearance of the
drug in plasma, per unit time, in accordance with its bioavailability).
GraphPad Prism Software Inc. (San Diego, CA), version 5.0, was used
for graphic representation, pharmacokinetic parameters determination
and statistical analysis. Data are presented as mean ± SEM. A two-
tailed unpaired Student's t-test was performed to identify signiﬁcant
between-group differences in normally distributed variables. Statistical
signiﬁcance was accepted at the 0.05 level.
Groups presented comparable characteristics (Table 1). However,
statistical differences between groups about two digoxin pharmacoki-
netic parameters due to carvedilol association were observed (Table 1
and Fig. 1): Table 1 shows that the parameter CL/F is lower in carvedilol
group compared to control and Fig. 1 shows that the Cp of digoxin ob-
tained 24 h after its administration is increased by the association
with this β-blocker.
In the case of drugs administered orally, it is difﬁcult to estimate ab-
solute bioavailability; thus, the apparent clearance, expressed by CL/F
ratio, is the plasma clearance rate for a particular drug per unit of
time, according to its bioavailability, when this drug is administered
by a systemic route different of intravenous. Our data allow us to sug-
gest that the combination of digoxin and carvedilol promotes theTable 1
Demographic/clinical characteristics anddigoxin pharmacokinetic parameters of the heart
failure patients under conventional digoxin therapy alone (control) or in combination
with carvedilol administration twice a day (carvedilol).
Variables Control (n = 3) Carvedilol (n = 5)
Age (years) 47.0 ± 2.5 50.2 ± 2.7
Weight (kg) 55.7 ± 8.2 73.6 ± 6.0
Height (m) 1.63 ± 0.66 1.74 ± 0.04
Creatinine (mg/dL) 1.87 ± 0.82 1.52 ± 0.15
Creatinine Clearance (mL/min) 49.00 ± 13.76 61.55 ± 4.42
Medications
Furosemide 2 5
ACEI/ARB 2 4
Omeprazole 2 2
Spironolactone 3 4
Digoxin pharmacokinetic parameters
AUC0-8 h (ng·h/mL) 6.38 ± 0.80 9.50 ± 1.14
AUC0-24 h (ng·h/mL) 17.60 ± 2.09 26.68 ± 3.31
Cmax (ng·mL−1) 1.05 ± 0.074 1.40 ± 0.12
Tmax (h) 3.67 ± 2.19 2.00 ± 0.55
CL/F (L/h/Kg) 0.237 ± 0.071 0.074 ± 0.019*
ACEI— angiotensin-converter enzyme inhibitors; ARB — angiotensin receptor blockers.
*P b 0.05 — carvedilol vs control.increase of drug fraction that reaches circulation and/or the decrease
of the body's ability to clear digoxin.
P-glycoprotein appears to play a signiﬁcant role in drug disposition
being digoxin and carvedilol substrates of this transport system [2,9,
10]. According to literature, men seem to have a higher activity relative
to women for this drug efﬂux transporter [9]. Tubular secretion of di-
goxin has been found to be mediated via P-glycoprotein, so carvedilol
association can promote basal-to-apical transport inhibition of digoxin
[9]. In addition, intestinal absorption of digoxin is primarily dominated
by the efﬂux process also mediated by P-glycoprotein on the luminal
side of the intestine; carvedilol associationmay be related to the inhibi-
tion of this efﬂux process [9]. Therefore, it is likely that P-glycoprotein
inhibition by carvedilol increases the absorption of digoxin, increasing
its bioavailability, and decreases the renal secretion of digoxin, reducing
its clearance, in males [2,9]. So the decrease of CL/F of digoxin is expect-
ed, as observed in the present work, due to its combination with carve-
dilol, since it may reﬂect a decrease of the clearance and/or an increase
of the absorption of digitalis.
This study was designed to determinewhether carvedilol treatment
is associated with changes on digoxin pharmacokinetic parameters in
males with heart failure, an effect assigned in many studies involving
hypertensive patients [5] and male healthy volunteers [6] in addition
to children [8] and older males [9] with heart failure. In the last case, a
crossover study, elderlymale patients had received a dosage of carvedil-
ol lower than that associated with beneﬁts in heart failure [1]. Our ﬁnd-
ings suggest that carvedilol therapy involving a dosage of this β-blocker
actually associated with beneﬁts in this pathology modulates digoxin
pharmacokinetics in younger male patients. In conclusion, concerning
the increase of the exposure to digoxin, when these agents are com-
bined, it is recommended the monitoring of serum digoxin levels and
the appraisal of its posology adjustment.
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